These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 36866388)

  • 1. High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.
    Yang H; Kang B; Ha Y; Lee SH; Kim I; Kim H; Lee WS; Kim G; Jung S; Rha SY; Gaillard VE; Cheon J; Kim C; Chon HJ
    JHEP Rep; 2023 Apr; 5(4):100672. PubMed ID: 36866388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma.
    Kim C; Yang H; Kim I; Kang B; Kim H; Kim H; Lee WS; Jung S; Lim HY; Cheon J; Chon HJ
    JAMA Oncol; 2022 Dec; 8(12):1825-1829. PubMed ID: 36264560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study.
    Kudo M; Finn RS; Galle PR; Zhu AX; Ducreux M; Cheng AL; Ikeda M; Tsuchiya K; Aoki KI; Jia J; Lencioni R
    Liver Cancer; 2023 Aug; 12(3):238-250. PubMed ID: 37767068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
    Teng W; Lin CC; Su CW; Lin PT; Hsieh YC; Chen WT; Ho MM; Wang CT; Chai PM; Hsieh JC; Lin CY; Lin SM
    Am J Cancer Res; 2022; 12(4):1899-1911. PubMed ID: 35530282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma.
    Song YS; Yang H; Kang B; Cheon J; Kim I; Kim H; Lee WS; Sang YB; Jung S; Lim HY; Gaillard VE; Kim C; Chon HJ
    Liver Cancer; 2024 Feb; 13(1):89-98. PubMed ID: 38344445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atezolizumab Plus Bevacizumab Versus Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Lu J; Lin X; Teng H; Zheng Y
    J Clin Pharmacol; 2024 Jun; 64(6):643-651. PubMed ID: 38311835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment.
    Chon YE; Cheon J; Kim H; Kang B; Ha Y; Kim DY; Hwang SG; Chon HJ; Kim BK
    Cancer Med; 2023 Feb; 12(3):2731-2738. PubMed ID: 35997637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
    Tamaki N; Tada T; Kurosaki M; Yasui Y; Ochi H; Mashiba T; Sakamoto A; Marusawa H; Narita R; Uchida Y; Akahane T; Kondo M; Mori N; Takaki S; Tsuji K; Kobashi H; Kusakabe A; Furuta K; Arai H; Nonogi M; Ogawa C; Sato T; Tamada T; Nakamura S; Hasebe C; Tsuchiya K; Izumi N
    Invest New Drugs; 2022 Dec; 40(6):1290-1297. PubMed ID: 36152108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.
    Vithayathil M; D'Alessio A; Fulgenzi CAM; Nishida N; Schönlein M; von Felden J; Schulze K; Wege H; Saeed A; Wietharn B; Hildebrand H; Wu L; Ang C; Marron TU; Weinmann A; Galle PR; Bettinger D; Bengsch B; Vogel A; Balcar L; Scheiner B; Lee PC; Huang YH; Amara S; Muzaffar M; Naqash AR; Cammarota A; Zanuso V; Pressiani T; Pinter M; Cortellini A; Kudo M; Rimassa L; Pinato DJ; Sharma R
    Hepatol Int; 2023 Aug; 17(4):904-914. PubMed ID: 37005953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment.
    Hosoda S; Suda G; Sho T; Ogawa K; Kimura M; Yang Z; Yoshida S; Kubo A; Tokuchi Y; Kitagataya T; Maehara O; Ohnishi S; Nakamura A; Yamada R; Ohara M; Kawagishi N; Natsuizaka M; Nakai M; Morikawa K; Furuya K; Baba M; Yamamoto Y; Suzuki K; Izumi T; Meguro T; Terashita K; Ito J; Miyagishima T; Sakamoto N
    Liver Cancer; 2023 Jun; 12(2):156-170. PubMed ID: 37325489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab.
    Okuno M; Ishii T; Ichida A; Soyama A; Takemura N; Hirono S; Eguchi S; Hasegawa K; Sasaki Y; Uemura K; Kokudo N; Hatano E
    BMC Cancer; 2023 Aug; 23(1):780. PubMed ID: 37605169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab and Atezolizumab for Unresectable Hepatocellular Carcinoma: Real-world Data in Taiwan-Tainan Medical Oncology Group H01 Trial.
    Lee YC; Huang WT; Lee MY; Tsao CJ; Feng YH
    In Vivo; 2023; 37(1):454-460. PubMed ID: 36593061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review.
    Ahmed F; Onwumeh-Okwundu J; Yukselen Z; Endaya Coronel MK; Zaidi M; Guntipalli P; Garimella V; Gudapati S; Mezidor MD; Andrews K; Mouchli M; Shahini E
    World J Gastrointest Oncol; 2021 Nov; 13(11):1813-1832. PubMed ID: 34853653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma.
    Cheon J; Yoo C; Hong JY; Kim HS; Lee DW; Lee MA; Kim JW; Kim I; Oh SB; Hwang JE; Chon HJ; Lim HY
    Liver Int; 2022 Mar; 42(3):674-681. PubMed ID: 34792284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.
    Scheiner B; Pomej K; Kirstein MM; Hucke F; Finkelmeier F; Waidmann O; Himmelsbach V; Schulze K; von Felden J; Fründt TW; Stadler M; Heinzl H; Shmanko K; Spahn S; Radu P; Siebenhüner AR; Mertens JC; Rahbari NN; Kütting F; Waldschmidt DT; Ebert MP; Teufel A; De Dosso S; Pinato DJ; Pressiani T; Meischl T; Balcar L; Müller C; Mandorfer M; Reiberger T; Trauner M; Personeni N; Rimassa L; Bitzer M; Trojan J; Weinmann A; Wege H; Dufour JF; Peck-Radosavljevic M; Vogel A; Pinter M
    J Hepatol; 2022 Feb; 76(2):353-363. PubMed ID: 34648895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
    Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Shibata H; Aoki T; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Kaibori M; Hiasa Y; Kudo M;
    Cancer Med; 2023 Jan; 12(1):325-334. PubMed ID: 35666040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma.
    Chuma M; Uojima H; Toyoda H; Hiraoka A; Arase Y; Atsukawa M; Itokawa N; Okubo T; Tada T; Numata K; Morimoto M; Sugimori M; Nozaki A; Iwasaki S; Yasuda S; Koshiyama Y; Mishima Y; Tsuruya K; Tokoro C; Miura Y; Hidaka H; Kumada T; Kusano C; Kagawa T; Maeda S
    Hepatol Int; 2024 Oct; 18(5):1472-1485. PubMed ID: 38963640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis.
    Suzuki T; Matsuura K; Suzuki Y; Okumura F; Nagura Y; Sobue S; Matoya S; Miyaki T; Kimura Y; Kusakabe A; Narahara S; Tokunaga T; Nagaoka K; Kuroyanagi K; Kawamura H; Kuno K; Fujiwara K; Nojiri S; Kataoka H; Tanaka Y
    Cancer Med; 2024 Jan; 13(1):e6876. PubMed ID: 38133557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.